Florbetapir meets Alzheimer's endpoints

Avid Radiopharmaceuticals Inc. (Philadelphia, Pa.) said florbetapir met the co-primary endpoints in the Phase III Image-to-Autopsy trial to diagnose Alzheimer's disease (AD). Beta amyloid levels from positron emission tomography (PET) images in patients receiving a single IV dose of florbetapir prior to the scan showed a significant correlation to post-mortem cortical beta amyloid levels at autopsy, and there was significant specificity for the presence or absence of beta amyloid levels on the PET images. The data included the first 35 patients to come to autopsy in the single-blind, U.S. trial. ...